West Pharma Q4 revenue -3% to $708.7M, adj. EPS $1.77; FY23 guidance $7.25-$7.40, $1B buyback

WEST PHARMACEUTICAL SERVICES INC

2022-FY EPS reported $7.73 revenue$2,886,900,000

Q4 net sales $708.7M (-3.0% reported, +2.6% organic); reported EPS $1.36, adjusted EPS $1.77.
Full-year 2022 net sales $2.887B (+2.0% reported, +7.7% organic); reported EPS $7.73, adjusted EPS $8.58.
FY 2023 guidance: net sales $2.935-2.960B, adj. EPS $7.25-7.40; COVID sales ~$85M (vs $388M in 2022).
Board approved new $1.0B share repurchase program, no expiration; prior program expired Dec 31, 2022.
Operating cash flow $724.0M (+24%); free cash flow $439.4M (+32.9%); capex $284.6M.

item 2.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WEST PHARMACEUTICAL SERVICES INC reported full-year 2023 results: revenue $2.935 billion to $2.960 billion, EPS $7.25 to $7.40. Guidance initiated.

Period: full-year 2023
Revenue: $2.935 billion to $2.960 billion
EPS: $7.25 to $7.40
Guidance: initiated
Result: guidance update

Exact text from the filing

The Company is introducing full-year 2023 financial guidance of net sales in a range of $2.935 billion to $2.960 billion and adjusted-diluted EPS in a range of $7.25 to $7.40.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2022 results: revenue $708.7 million. Guidance initiated.

Period: the fourth-quarter and full-year 2022
Revenue: $708.7 million
Guidance: initiated
Result: reported results

Exact text from the filing

West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2022 and introduced full-year 2023 financial guidance. Fourth-Quarter and Full-Year 2022 Summary (comparisons to prior-year period) • Fourth-quarter 2022 net sales of $708.7 million declined 3.0%; organic net sales growth was 2.6%

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

WEST PHARMACEUTICAL SERVICES INC filing history →

Source: SEC EDGAR

accession 0000105770-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.